Drug Profile
DNV 3837
Alternative Names: DNV 3681; DNV-3837; MCB-3681; MCB-3837; OxaquinLatest Information Update: 03 Nov 2022
Price :
$50
*
At a glance
- Originator Morphochem AG
- Developer Biovertis AG; Deinove; Evotec SE; United States Army Medical Research Institute of Infectious Diseases
- Class Acetamides; Antibacterials; Carboxylic acids; Cyclopropanes; Fluorobenzenes; Oxazolidinones; Phenyl ethers; Phosphates; Piperidines; Quinolines; Quinolones; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors; Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Clostridium difficile infections
- Preclinical Anthrax; Tularaemia
- No development reported Bacterial infections
- Discontinued Nosocomial infections
Most Recent Events
- 20 Oct 2022 Preclinical trials in Anthrax in USA (IV) (Deinove pipeline; October 2022)
- 20 Oct 2022 Preclinical trials in Tularaemia in USA (IV) (Deinove pipeline; October 2022)
- 19 Oct 2022 Chemical structure added